Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients.Methods For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible. Patients were given 1200 mg intravenous atezolizumab every 21 days until progression. The primary endpoint was independently confirmed objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 (central review), assessed in prespecified subgroups based on PD-L1 expression and in all patients. All participants who received one or more doses of atezolizumab were included in the primary and safety analyses. This study was registered with ClinicalTrials.gov, number NCT02108652.Findings Between June 9, 2014, and March 30, 2015, we enrolled 123 patients, of whom 119 received one or more doses of atezolizumab. At 17·2 months' median follow-up, the objective response rate was 23% (95% CI 16 to 31), the complete response rate was 9% (n=11), and 19 of 27 responses were ongoing. Median response duration was not reached. Responses occurred across all PD-L1 and poor prognostic factor subgroups. Median progression-free survival was 2·7 months (2·1 to 4·2). Median overall survival was 15·9 months (10·4 to not estimable). Tumour mutation load was associated with response. Treatment-related adverse events that occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients). One treatment-related death (sepsis) occurred. Nine (8%) patients had an adverse event leading to treatment discontinuation. Immune-mediated events occurred in 14 (12%) patients.Interpretation Atezolizumab showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use in untreated metastatic urothelial cancer.Funding F Hoffmann-La Roche, Genentech.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“however, in other cases, substantial responses can be observed in some patients with PD-L1-negative tumors, which highlights the difficulty of using PD-L1 as a single biomarker (34,143,144).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [144]
In the citing paper
“A correlation between PD-L1 expression on tumor cells and clinical response is seen in certain circumstances (e.g., in NSCLC); however, in other cases, substantial responses can be observed in some patients with PD-L1-negative tumors, which highlights the difficulty of using PD-L1 as a single biomarker (34,143,144).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationComprehensive molecular characterization of urothelial bladder carcinoma
Weinstein, J. N., Akbani, R., Broom, B. M., Wang, W., Verhaak, R. G. W., Liu, W., Ju, Z., Motter, T., Peng, B., Ryan, M., et al. (2014) · Nature · doi:10.1038/nature12965 · Cited by 3,142
Self-citationComprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Self-citationvon der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.-L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.009 · Cited by 1,716
Self-citationLoehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., & Lowe, B. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1066 · Cited by 981
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Damrauer, J. S., Hoadley, K. A., Chism, D. D., Fan, C., Tiganelli, C. J., Wobker, S. E., Yeh, J. J., Milowsky, M. I., Iyer, G., Parker, J. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318376111 · Cited by 877
De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3571 · Cited by 778
Bajorin, D. F., Dodd, P. M., Mazumdar, M., Fazzari, M., McCaffrey, J. A., Scher, H. I., Herr, H., Higgins, G., & Boyle, M. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3173 · Cited by 728
Self-citationTreatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., Dreicer, R., Vogelzang, N., Sternberg, C. N., Bajorin, D. F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8433 · Cited by 705
Self-citationMcDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
Self-citationBellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., Boehle, A., Chevreau, C., Paz-Ares, L., Laufman, L. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6979 · Cited by 526
Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., Dreicer, R., Vogelzang, N., Sternberg, C., Bajorin, D. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70275-8 · Cited by 356
Self-citationBladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
Bellmunt, J., Orsola, A., Leow, J. J., Wiegel, T., De Santis, M., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu223 · Cited by 335
Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction
Taylor, J. A., & Kuchel, G. A. (2009) · Nature Reviews Urology · doi:10.1038/ncpuro1315 · Cited by 88
Santis, M. D., Wiechno, P., Joaquim Bellmunt, B., Lucas, C., Su, W., Albiges, L. K., Lin, C.-C., Senkus, E., Fléchon, A., Mourey, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv609 · Cited by 55
Self-citationNecchi, A., Pond, G. R., Raggi, D., Giannatempo, P., Vogelzang, N. J., Grivas, P. D., Galsky, M. D., Joaquim Bellmunt, B., & Sonpavde, G. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.05.003 · Cited by 54
Self-citationSonpavde, G., Galsky, M. D., Latini, D. M., & Chen, G. J. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.11.016 · Cited by 50
Self-citationUpper tract urothelial carcinoma: special considerations.
Hutchinson, R. C., Haddad, A., Sagalowsky, A. I., & Margulis, V. (2016) · PubMed · Cited by 11
2624 The effectiveness of chemotherapy in “real world” patients with metastatic bladder cancer
Galsky, M. D., Pal, S. K., Lin, S., Ogale, S. S., Simpson, J., Schiff, C., & Sonpavde, G. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31442-3 · Cited by 3
Self-citation
Cited by
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Self-citationImmune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
“estimation [37, 69] and panels tested to date (F1CDx and MSK-IMPACT), have demonstrated their predictive ability for ICB response [4, 37, 70-73] (Table 1).”
MethodTop 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Self-citationRegulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Metadata
- Authors
- Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., Dawson, N. A., van der Heijden, M. S., Dreicer, R., Srinivas, S., Retz, M. M., Joseph, R. W., Drakaki, A., Vaishampayan, U. N., Sridhar, S. S., Quinn, D. I., Durán, I., Shaffer, D. R., Eigl, B. J., Grivas, P. D., Yu, E. Y., Li, S., Kadel, E. E., Boyd, Z., Bourgon, R., Hegde, P. S., Mariathasan, S., Thåström, A., Abidoye, O. O., Fine, G. D., & Bajorin, D. F.
- Affiliations
- NYU Langone Health (US)
- Tisch Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Queen Mary University of London (GB)
- Yale University (US)
- Université Paris-Saclay (FR)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Sidney Kimmel Cancer Center (US)
- MedStar Georgetown University Hospital (US)
- University of Virginia (US)
- Stanford Medicine (US)
- TUM Klinikum (DE)
- Mayo Clinic (US)
- University of California, Los Angeles (US)
- Wayne State University (US)
- Princess Margaret Cancer Centre (CA)
- USC Norris Comprehensive Cancer Center (US)
- Instituto de Biomedicina de Sevilla (ES)
- New York Oncology Hematology (US)
- BC Cancer Agency (CA)
- Cleveland Clinic (US)
- University of Washington (US)
- Genentech (US)
- Corresponding author
- Balar, Arjun V
- ORCID
- Balar, Arjun V
- Galsky, Matthew D
- Rosenberg, Jonathan E
- Powles, Thomas
- Petrylak, Daniel P
- Loriot, Yohann
- Necchi, Andrea
- Hoffman-Censits, Jean
- Dawson, Nancy A
- Dreicer, Robert
- Joseph, Richard W
- Drakaki, Alexandra
- Vaishampayan, Ulka N
- Sridhar, Srikala S
- Quinn, David I
- Durán, Ignacio
- Shaffer, David R
- Eigl, Bernhard J
- Grivas, Petros D
- Yu, Evan Y
- Li, Shi
- Kadel, Edward E
- Bourgon, Richard
- Mariathasan, Sanjeev
- Bajorin, Dean F
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 389
- Issue
- 10064
- Pages
- 67-76
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC5568632
- OpenAlex
- W2559804019
- Cited by
- 2,199
- References
- 29
- Citations by year
- 2026: 83 · 2025: 166 · 2024: 206 · 2023: 258 · 2022: 263 · 2021: 294 · 2020: 280 · 2019: 241 · 2018: 247 · 2017: 152
- FWCI
- 238.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Celgene
- F. Hoffmann-La Roche
- Eisai
- Astellas Pharma
- Ipsen
- Genentech
- EMD Serono
- National Cancer Institute (P30CA008748, P30CA015083)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- atezolizumab, urothelial carcinoma, metastatic urothelial carcinoma, locally advanced urothelial carcinoma, cisplatin-ineligible patients, PD-L1 inhibitors, first-line therapy, objective response rate, PD-L1 expression, progression-free survival, overall survival, immune-related adverse events, sepsis, non-relapse mortality
- MeSH terms
- Contraindications, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Transitional Cell, Cisplatin, Female, Humans, Infusions, Intravenous, Lymphatic Metastasis, Male, Middle Aged, Biomarkers, Tumor, Urologic Neoplasms, Kaplan-Meier Estimate, B7-H1 Antigen, Antibodies, Monoclonal, Humanized, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.